Brief: GSK Reports 61% Overall Response Rate For Ris-Rez In Phase IB Trial
Sun 23:16
BRIEF-GSK Reports 61% Overall Response Rate For Ris-Rez In Phase IB Trial Oct 18 (Reuters) - GSK plc GSK.L:
GSK - REPORTS 61% OVERALL RESPONSE RATE FOR RIS-REZ IN PHASE IB TRIAL
Source text: [ID:]
Further company coverage: GSK.L
((Reuters.Briefs@thomsonreuters.com;))